Answers are grounded in this paper and cite their sources.
Regulatory agencies focus on the N-nitroso Drug Substance Related Impurities (NDSRIs) for the safety and efficacy of the pharmaceuticals. This study highlights the control and detection of NDSRI impurity in the broad-spectrum antibiotic moxifloxacin (MOX). The objective of the present study is to develop a highly sensitive, rapid, and novel LC-QqQ-MS/MS method for the simultaneous trace-level quantification of N-Nitroso Moxifloxacin (N-MOX) and di-Nitroso pyrrolopiperidine (DNPP) in MOX drug substance and drug products. According to the Carcinogenicity Potency Categorization Approach (CPCA), N-MOX and DNPP are classified into potency category 4, with an acceptable intake (AI) of 1500 ng/day. Chromatographic separation was achieved using a Waters Cortecs T3 C18 column (100 mm × 3.0 mm, 2.7 µm) with 0.1 % formic acid and acetonitrile as mobile phases in gradient elution mode at a flow rate of 0.3 mL/min. Triple quadrupole mass spectrometry with electrospray ionization (ESI) in multiple reaction monitoring (MRM) was used for quantification. The specific mass transitions are m/z 431.0 → 386.0 for N-MOX and 185.1 → 138.1 for DNPP. The developed method was successfully validated, and the results were within the acceptable range according to ICH guidelines. Moreover, we evaluated the eco-friendliness and greenness of the current method using enhanced tools. The results indicated a low environmental impact in terms of analysis time, solvent consumption, waste production, and sample quantity required. The method was successfully applied to quantify N-MOX in commercial MOX tablets and eye drops with a shorter run time; hence, it can quantify the presence of N-MOX and DNPP to ensure human safety and public health from using MOX formulation products.
No takes yet. Share an insight, caveat, or question.
Nakka et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: